期刊
CANCER CYTOPATHOLOGY
卷 122, 期 10, 页码 730-736出版社
WILEY
DOI: 10.1002/cncy.21471
关键词
public databases; somatic variants; actionable mutations; clinical genomic reports; cancer targeted therapies
Next-generation sequencing (NGS) has become an important tool for identifying clinically relevant variants in both inherited disorders and oncology. Variants annotation that enables the creation of meaningful clinical reports often requires mining multiple publicly available databases. There are a number of such resources that have been designed to catalog and mine a plethora of germline variants or mutations. However, when analyzing tumor specimens in clinical settings, one may need to use different or ancillary resources that are specific for somatic variants or actionable mutations that may have clinical or treatment implications. The purpose of this review is to recapitulate the state of the art of somatic variation databases, which can aid in the clinical interpretation of NGS-based assays in oncology. In addition, the current need for collating various annotation sources into one-stop solutions to facilitate faster query execution and better integration into existing laboratory information systems are discussed. Cancer (Cancer Cytopathol) 2014;122:730-736. (c) 2014 The Authors. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This review focuses on the publicly available resources for the annotation of somatic variants found by next-generation sequencing (NGS) technologies applied to mutational analyses of tumor specimens in clinical settings. The characteristics of the existing databases as well as the ideal tools needed to comprehensively annotate mutations for the creation of clinically relevant reports for oncology are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据